Valeria Magni, Marianna Adamo, Elisa Pezzola, Antonio Popolo Rubbio, Cristina Giannini, Giulia Masiero, Carmelo Grasso, Paolo Denti, Arturo Giordano, Federico De Marco, Antonio L Bartorelli, Matteo Montorfano, Cosmo Godino, Cesare Baldi, Francesco De Felice, Annalisa Mongiardo, Ida Monteforte, Emmanuel Villa, Gabriele Crimi, Maurizio Tusa, Luca Testa, Lisa Serafini, Dario Cani, Giacinta Guarini, Alda Huqi, Marco Sesana, Marco De Carlo, Francesco Maisano, Giuseppe Tarantini, Corrado Tamburino, Francesco Bedogni, Marco Metra
{"title":"心衰严重程度对二尖瓣经导管边缘到边缘瓣膜修复术死亡率益处的影响。","authors":"Valeria Magni, Marianna Adamo, Elisa Pezzola, Antonio Popolo Rubbio, Cristina Giannini, Giulia Masiero, Carmelo Grasso, Paolo Denti, Arturo Giordano, Federico De Marco, Antonio L Bartorelli, Matteo Montorfano, Cosmo Godino, Cesare Baldi, Francesco De Felice, Annalisa Mongiardo, Ida Monteforte, Emmanuel Villa, Gabriele Crimi, Maurizio Tusa, Luca Testa, Lisa Serafini, Dario Cani, Giacinta Guarini, Alda Huqi, Marco Sesana, Marco De Carlo, Francesco Maisano, Giuseppe Tarantini, Corrado Tamburino, Francesco Bedogni, Marco Metra","doi":"10.1007/s00392-024-02490-7","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>To assess the interaction between heart failure (HF) severity and optimal reduction of secondary mitral regurgitation (SMR) on mortality in patients undergoing transcatheter edge-to-edge repair (M-TEER).</p><p><strong>Methods and results: </strong>Among 1656 patients included in the Italian Society of Interventional Cardiology (GIse) registry Of Transcatheter treatment of mitral valve regurgitaTiOn (GIOTTO) 984 had SMR and complete data on advanced HF. Advanced HF was defined as NYHA class III or IV, left ventricular ejection fraction ≤ 30%, and > 1 HF hospitalization during the last 12 months. Optimal M-TEER was defined as residual SMR ≤ 1 + at discharge. One hundred sixteen patients (11.8%) had advanced HF. Achievement of an optimal SMR reduction was similar in patients with and without advanced HF (65% and 60% respectively). Advanced HF was an independent predictor of 2-year all-cause death (adjusted HR 1.52, 95% CI 1.09-2.10). Optimal M-TEER, as compared to a no-optimal M-TEER, was associated with a reduced risk of death both in patients with advanced (HR 0.55, 95% CI 0.32-0.97; p = 0.039) and no-advanced HF (HR 0.59, 95% CI 0.46-0.78; p < 0.001; p = 0.778 for interaction).</p><p><strong>Conclusions: </strong>Advanced HF is associated with poor outcome in patients undergoing M-TEER. However, an optimal SMR reduction reduces the risk of 2-year mortality regardless of HF severity.</p>","PeriodicalId":10474,"journal":{"name":"Clinical Research in Cardiology","volume":" ","pages":"836-845"},"PeriodicalIF":3.8000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12202617/pdf/","citationCount":"0","resultStr":"{\"title\":\"Impact of heart failure severity on the mortality benefit of mitral transcatheter edge-to-edge valve repair.\",\"authors\":\"Valeria Magni, Marianna Adamo, Elisa Pezzola, Antonio Popolo Rubbio, Cristina Giannini, Giulia Masiero, Carmelo Grasso, Paolo Denti, Arturo Giordano, Federico De Marco, Antonio L Bartorelli, Matteo Montorfano, Cosmo Godino, Cesare Baldi, Francesco De Felice, Annalisa Mongiardo, Ida Monteforte, Emmanuel Villa, Gabriele Crimi, Maurizio Tusa, Luca Testa, Lisa Serafini, Dario Cani, Giacinta Guarini, Alda Huqi, Marco Sesana, Marco De Carlo, Francesco Maisano, Giuseppe Tarantini, Corrado Tamburino, Francesco Bedogni, Marco Metra\",\"doi\":\"10.1007/s00392-024-02490-7\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>To assess the interaction between heart failure (HF) severity and optimal reduction of secondary mitral regurgitation (SMR) on mortality in patients undergoing transcatheter edge-to-edge repair (M-TEER).</p><p><strong>Methods and results: </strong>Among 1656 patients included in the Italian Society of Interventional Cardiology (GIse) registry Of Transcatheter treatment of mitral valve regurgitaTiOn (GIOTTO) 984 had SMR and complete data on advanced HF. Advanced HF was defined as NYHA class III or IV, left ventricular ejection fraction ≤ 30%, and > 1 HF hospitalization during the last 12 months. Optimal M-TEER was defined as residual SMR ≤ 1 + at discharge. One hundred sixteen patients (11.8%) had advanced HF. Achievement of an optimal SMR reduction was similar in patients with and without advanced HF (65% and 60% respectively). Advanced HF was an independent predictor of 2-year all-cause death (adjusted HR 1.52, 95% CI 1.09-2.10). Optimal M-TEER, as compared to a no-optimal M-TEER, was associated with a reduced risk of death both in patients with advanced (HR 0.55, 95% CI 0.32-0.97; p = 0.039) and no-advanced HF (HR 0.59, 95% CI 0.46-0.78; p < 0.001; p = 0.778 for interaction).</p><p><strong>Conclusions: </strong>Advanced HF is associated with poor outcome in patients undergoing M-TEER. However, an optimal SMR reduction reduces the risk of 2-year mortality regardless of HF severity.</p>\",\"PeriodicalId\":10474,\"journal\":{\"name\":\"Clinical Research in Cardiology\",\"volume\":\" \",\"pages\":\"836-845\"},\"PeriodicalIF\":3.8000,\"publicationDate\":\"2025-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12202617/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Research in Cardiology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s00392-024-02490-7\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/7/24 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Research in Cardiology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00392-024-02490-7","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/7/24 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
Impact of heart failure severity on the mortality benefit of mitral transcatheter edge-to-edge valve repair.
Background: To assess the interaction between heart failure (HF) severity and optimal reduction of secondary mitral regurgitation (SMR) on mortality in patients undergoing transcatheter edge-to-edge repair (M-TEER).
Methods and results: Among 1656 patients included in the Italian Society of Interventional Cardiology (GIse) registry Of Transcatheter treatment of mitral valve regurgitaTiOn (GIOTTO) 984 had SMR and complete data on advanced HF. Advanced HF was defined as NYHA class III or IV, left ventricular ejection fraction ≤ 30%, and > 1 HF hospitalization during the last 12 months. Optimal M-TEER was defined as residual SMR ≤ 1 + at discharge. One hundred sixteen patients (11.8%) had advanced HF. Achievement of an optimal SMR reduction was similar in patients with and without advanced HF (65% and 60% respectively). Advanced HF was an independent predictor of 2-year all-cause death (adjusted HR 1.52, 95% CI 1.09-2.10). Optimal M-TEER, as compared to a no-optimal M-TEER, was associated with a reduced risk of death both in patients with advanced (HR 0.55, 95% CI 0.32-0.97; p = 0.039) and no-advanced HF (HR 0.59, 95% CI 0.46-0.78; p < 0.001; p = 0.778 for interaction).
Conclusions: Advanced HF is associated with poor outcome in patients undergoing M-TEER. However, an optimal SMR reduction reduces the risk of 2-year mortality regardless of HF severity.
期刊介绍:
Clinical Research in Cardiology is an international journal for clinical cardiovascular research. It provides a forum for original and review articles as well as critical perspective articles. Articles are only accepted if they meet stringent scientific standards and have undergone peer review. The journal regularly receives articles from the field of clinical cardiology, angiology, as well as heart and vascular surgery.
As the official journal of the German Cardiac Society, it gives a current and competent survey on the diagnosis and therapy of heart and vascular diseases.